References

[1]COMPAAN D M,HYMOWITZ S G.The crystal structure of the costimulatory OX40-OX40Lcomplex[J].Structure,2006,14(8):1321-1330.

[2]WILLOUGHBY J,GRIFFITHS J,TEWS I,et al.OX40:structure and function-what questions remain?[J].Molecular Immunology,2017,83:13-22.

[3]周杨，刘诚林，刘俊逸，等.OX40/OX40L分子在人活化T细胞上的表达特性及其生物学功能研究[J].中国血液流变学杂志，2016,26(2):143-147.ZHOU Y,LIU C L,LIU J Y,et al.Study on OX40/OX40Lexpression characteristics of activated human T cells and their biological function[J].Chinese Journal of Hemorheology,2016,26(2):143-147.

[4]TOENNIES H M,GREEN J M,ARCH R H.Expression of CD30and OX40on T lymphocyte subsets is controlled by distinct regulatory mechanisms[J].Journal of Leucocyte Biology,2004,75(2):350-357.

[5]SCHETTINI N,PACETTI L,CORAZZA M,et al.The role of OX40-OX40Laxis in the pathogenesis of atopic dermatitis[J].Dermatitis,2025,36(1):28-36.

[6]GUGLIELMO A,BORGHI A,ZENGARINI C,et al.OX40-OX40Laxis in cutaneous T-cell lymphomas:pathogenic,prognostic,and potential therapeutic perspectives[J].Biomolecules,2025,15(5):715.

[7]DONG L Y,HÜLSMEYER M,DÜRKOP H,et al.Human CD30:structural implications from epitope mapping and modeling studies[J].Journal of Molecular Recognition,2003,16(1):28-36.

[8]CROAGER E J,ABRAHAM L J.Characterisation of the human CD30ligand gene structure[J].Biochimica et Biophysica Acta(BBA):Gene Structure and Expression,1997,1353(3):231-235.

[9]ZHENG B,FIUMARA P,LI Y V,et al.MEK/ERK pathway is aberrantly active in Hodgkin disease:a signaling pathway shared by CD30,CD40,and RANK that regulates cell proliferation and survival[J].Blood,2003,102(3):1019-1027.

[10]NAKASHIMA M,UCHIMARU K.CD30 expression and its functions during the disease progression of adult T-cell leukemia/lymphoma[J].International Journal of Molecular Sciences,2023,24(10):8731.

[11]SOMADA S,MUTA H,NAKAMURA K,et al.CD30ligand/CD30interaction is involved in pathogenesis of inflammatory bowel disease[J].Digestive Diseases and Sciences,2012,57(8):2031-2037.

[12]PATTARINI L,TRICHOT C,BOGIATZI S,et al.TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand[J].Journal of Experimental Medicine,2017,214(5):1529-1546.

[13]LANE P.Role of OX40signals in coordinating CD4Tcell selection,migration,and cytokine differentiation in T helper(Th)1and Th2cells[J].Journal of Experimental Medicine,2000,191(2):201-206.

[14]FU N N,XIE F,SUN Z W,et al.The OX40/OX40L axis regulates T follicular helper cell differentiation:implications for autoimmune diseases[J].Frontiers in Immunology,2021,12:670637.

[15]JACQUEMIN C,AUGUSTO J F,SCHERLINGER M,et al.OX40L/OX40axis impairs follicular and natural Treg function in human SLE[J].JCI Insight,2018,3(24):e122167.

[16]KURATA I,MATSUMOTO I,OHYAMA A,et al.Potential involvement of OX40 in the regulation of autoantibody sialylation in arthritis[J].Annals of the Rheumatic Diseases,2019,78(11):1488-1496.

[17]ROGERS P R,SONG J,GRAMAGLIA I,et al.OX40promotes Bcl-xL and Bcl-2expression and is essential for long-term survival of CD4Tcells[J].Immunity,2001,15(3):445-455.

[18]MASSARELLI E,LAM V K,PARRA E R,et al.High OX-40expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer[J].Journal for Immunotherapy of Cancer,2019,7(1):351.

[19]WEIXLER B,CREMOSINI E,SORGE R,et al.OX40expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer[J].Oncotarget,2015,6(35):37588-37599.

[20]XIE K L,XU L,WU H,et al.OX40expression in hepatocellular carcinoma is associated with a distinct immune microenvironment,specific mutation signature,and poor prognosis[J].Oncoimmunology,2018,7(4):e1404214.

[21]VU M D,XIAO X,GAO W D,et al.OX40costimulation turns off Foxp3+Tregs[J].Blood,2007,110(7):2501-2510.

[22]KAWANA Y,SUGA H,KAMIJO H,et al.Roles of OX40and OX40ligand in mycosis fungoides and Sézary syndrome[J].International Journal of Molecular Sciences,2021,22(22):12576.

[23]BARBIERI A,DOLCINO M,TINAZZI E,et al.Characterization of CD30/CD30L+cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis[J].Journal of Immunology Research,2015,2015(1):729654.

[24]CABRERA C M,URRA J M,CARREÑO A,et al.Differential expression of CD30on CD3 Tlymphocytes in patients with systemic lupus erythematosus[J].Scandinavian Journal of Immunology,2013,78(3):306-312.

[25]SHINODA K,SUN X,OYAMADA A,et al.Requirement of CD30expression on CD4Tcells in the pathogenesis of experimental autoimmune encephalomyelitis[J].Journal of Neuroimmunology,2016,291:39-45.

[26]GUPTA R K,FIGUEROA D S,AY F,et al.Comparison of CD30Land OX40Lreveals CD30Las a promising therapeutic target in atopic dermatitis[J].Allergy,2025,80(2):500-512.

[27]ARTINGER K,KIRSCH A H,MOOSLECHNER A A,et al.Blockade of tumor necrosis factor superfamily members CD30and OX40abrogates disease activity in murine immune-mediated glomerulonephritis[J].Kidney International,2021,100(2):336-348.

[28]FUCHIWAKI T,SUN X,FUJIMURA K,et al.The central role of CD30L/CD30interactions in allergic rhinitis pathogenesis in mice[J].European Journal of Immunology,2011,41(10):2947-2954.

[29]GRACIAS D T,SETHI G S,MEHTA A K,et al.Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2cell reactivity and lung inflammation[J].Journal of Allergy and Clinical Immunology,2021,147(6):2316-2329.

[30]FENG S,ZHANG L,BIAN X H,et al.Role of the TSLP-DC-OX40Lpathway in asthma pathogenesis and airway inflammation in mice[J].Biochemistry and Cell Biology,2018,96(3):306-316.

[31]POLTE T,BEHRENDT A K,HANSEN G.Direct evidence for a critical role of CD30in the development of allergic asthma[J].Journal of Allergy and Clinical Immunology,2006,118(4):942-948.

[32]NAWAF M G,ULVMAR M H,WITHERS D R,et al.Concurrent OX40 and CD30ligand blockade abrogates the CD4-driven autoimmunity associated with CTLA4and PD1blockade while preserving excellent anti-CD8tumor immunity[J].Journal of Immunology,2017,199(3):974-981.

[33]WEIDINGER S,BIEBER T,CORK M J,et al.Safety and efficacy of amlitelimab,a fully human nondepleting,noncytotoxic antiOX40ligand monoclonal antibody,in atopic dermatitis:results of a phaseⅡa randomized placebo-controlled trial[J].British Journal of Dermatology,2023,189(5):531-539.

[34]GUTTMAN-YASSKY E,SIMPSON E,ESFANDIARI E,et al.Rocatinlimab:a novel T-cell rebalancing therapy targeting the OX40receptor in atopic dermatitis[J].Dermatology and Therapy,2025,15(11):3153-3171.

[35]GUTTMAN-YASSKY E,PAVEL A B,ZHOU L,et al.GBR830,an anti-OX40,improves skin gene signatures and clinical scores in patients with atopic dermatitis[J].Journal of Allergy and Clinical Immunology,2019,144(2):482-493.

[36]LU Y F,SHEN Y C,GUO C T,et al.IMG-007,a non-depleting anti-OX40 monoclonal antibody,reduced skin lesion severity and serum inflammatory markers in adults with moderate-tosevere atopic dermatitis in a phase 1b/2astudy[J].Journal of Investigative Dermatology,2025,145(11):e72.

[37]LEEUW T，ŠIMAIT E·D,HEYNINCK K,et al.Combined TNFαand OX40L targeting as a new treatment option for hidradenitis suppurativa[J].Journal of Allergy and Clinical Immunology:Global,2025,4(3):100483.

[38]GOUGH M J,RUBY C E,REDMOND W L,et al.OX40agonist therapy enhances CD8infiltration and decreases immune suppression in the tumor[J].Cancer Research,2008,68(13):5206-5215.

[39]JAHAN N,TALAT H,CURRY W T,et al.Agonist OX40immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells[J].Neuro-Oncology,2018,20(1):44-54.

[40]PICONESE S,VALZASINA B,COLOMBO M P,et al.OX40triggering blocks suppression by regulatory T cells and facilitates tumor rejection[J].Journal of Experimental Medicine,2008,205(4):825-839.

[41]KITAMURA N,MURATA S,UEKI T,et al.OX40costimulation can abrogate Foxp3+regulatory T cell-mediated suppression of antitumor immunity[J].International Journal of Cancer,2009,125(3):630-638.

[42]LINCH S N,MCNAMARA M J,REDMOND W L.OX40agonists and combination immunotherapy:putting the pedal to the metal[J].Frontiers in Oncology,2015,5:34.

[43]ARANDA F,VACCHELLI E,EGGERMONT A,et al.Trial watch:immunostimulatory monoclonal antibodies in cancer therapy[J].Oncoimmunology,2014,3(2):e27297.

[44]DIAB A,HAMID O,THOMPSON J A,et al.A phaseⅠ，openlabel,dose-escalation study of the OX40agonist Ivuxolimab in patients with locally advanced or metastatic cancers[J].Clinical Cancer Research,2022,28(1):71-83.

[45]GOLDMAN J W,PIHA-PAUL S A,CURTI B,et al.Safety and tolerability of MEDI0562,an OX40 agonist mAb,in combination with Durvalumab or Tremelimumab in adult patients with advanced solid tumors[J].Clinical Cancer Research,2022,28(17):3709-3719.

[46]GLISSON B S,LEIDNER R S,FERRIS R L,et al.Safety and clinical activity of MEDI0562,a humanized OX40agonist monoclonal antibody,in adult patients with advanced solid tumors[J].Clinical Cancer Research,2020,26(20):5358-5367.

[47]JOHNSON M,HONG D,BRAÑA I,et al.First-in-human,phase1dose escalation study of SL-279252,a hexameric PD1-FcOX40Lfusion protein,in patients with advanced solid tumors and lymphoma[J].Investigational New Drugs,2025,43(2):284-292.

[48]FERNÁNDEZ-CODINA A,NEVSKAYA T,BARON M,et al.Brentuximab Vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis,an open-label trial[J].Rheumatology,2025,64(3):1476-1481.

[49]YOUNES A,YASOTHAN U,KIRKPATRICK P.Brentuximab Vedotin[J].Nature Reviews Drug Discovery,2012,11:19.

[50]ANSELL S M,RADFORD J,CONNORS J M,et al.Overall survival with Brentuximab Vedotin in stageⅢorⅣHodgkin′s lymphoma[J].New England Journal of Medicine,2022,387(4):310-320.

[51]HAMBLETT K J,COCHRAN J,SNEAD K,et al.SGN-35C:a novel CD30-directed antibody-drug conjugate for the treatment of lymphomas[J].Blood,2023,142(suppl 1):1440.

[52]THIRUVENGADAM S,POH C,LYNCH R,et al.First-in-human,open-label,phase 1study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1inhibitor payload,PF-08046044(35C),in patients with relapsed/refractory lymphomas:updated safety,PK,preliminary efficacy and ctDNAanalysis from dose escalation[J].Blood,2025,146(suppl1):155.

[53]SHEN Y J,YANG T,CAO X M,et al.Conjugation of DM1to anti-CD30antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity[J].mAbs,2019,11(6):1149-1161.

[54]MOSKOWITZ A,HARSTRICK A,EMIG M,et al.AFM13 in combination with allogeneic natural killer cells(AB-101)in relapsed or refractory Hodgkin lymphoma and CD30+peripheral T-cell lymphoma:aphase 2study(LuminICE)[J].Blood,2023,142(suppl 1):4855.

[55]WANG D,ZENG C,XU B,et al.Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+lymphoma patients[J].Blood Cancer Journal,2020,10(1):8.